Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. - Wikidata - awgldk - TriplyDB

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

http://www.wikidata.org/entity/Q43179865

about

Dendritic-Tumor Fusion Cell-Based Cancer Vaccines Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines Boosting Tumor-Specific Immunity Using PDT Trial Watch-Oncolytic viruses and cancer therapy Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives N-dihydrogalactochitosan as a potent immune activator for dendritic cells.Generation of dendritic cell-based vaccine using high hydrostatic pressure for non-small cell lung cancer immunotherapy Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Cancer stem cell vaccine expressing ESAT-6-gpi and IL-21 inhibits melanoma growth and metastases Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal The oncolytic peptide LTX-315 triggers immunogenic cell death.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer.Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.Autophagy, a major adaptation pathway shaping cancer cell death and anticancer immunity responses following photodynamic therapy.Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.Generation of T cell effectors using tumor cell-loaded dendritic cells for adoptive T cell therapy.Use of nanotechnology for improved pharmacokinetics and activity of immunogenic cell death inducers used in cancer chemotherapy.Understanding dendritic cell immunotherapy in ovarian cancer.Immunotherapy of colorectal cancer: new perspectives after a long path.Editorial: Immunogenic Cell Death in Cancer: From Benchside Research to Bedside Reality.Nano-Pulse Stimulation is a physical modality that can trigger immunogenic tumor cell death.Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death.Strategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma.Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice.Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018.Immune recognition of irradiated cancer cells.Mathematical model of tumor volume dynamics in mice treated with electrochemotherapy.Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo.Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy.Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells.Calreticulin and type I interferon: An unsuspected connection.Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide

P2860

Q26744827-E8147D5C-B2DF-40B4-820B-19ABC3DC6EE0 Q26772715-59774799-8F16-4D05-8C76-DD2FC798BD51 Q28067203-A445BA2B-5D19-49E1-8FBA-9AF3A5A9CF5C Q28072347-7CC23004-3FFC-404A-8B62-0D8DBFE55457 Q30842176-00D0AB73-BC3C-4DFC-9426-E83B3CAB5320 Q33679505-B66E97F8-11F7-4ACA-BC2A-9F3779980B57 Q36234323-CBD03E4B-7539-445C-85B7-36A3A99136DD Q36277032-A3522D30-83C2-415B-81C7-5A347BF5175D Q36301061-6BDC1283-86A0-4A89-8CBF-0EA250BF171D Q36309496-C1FEB331-30A7-4DD9-B06B-1181661EFEBE Q36413628-5762C3F6-61B6-4F2C-9EC8-7A53EA8C83A4 Q36774984-0224253C-1791-4F17-9624-CF88253E0626 Q37079141-137F025D-9F3D-4438-84CC-B51B0988A45F Q37295663-ED119597-CF4E-4764-8E5A-7E1077218A8B Q37634941-6885E719-6913-49B9-80D5-F6835C19C20A Q37701461-A0772781-1283-424D-8742-9638A7EDA1B0 Q38349813-07A9F504-E7B6-4BD1-A7E0-E992B0A5F5AB Q38366904-8BFA7F1C-F586-4C9C-9365-899FA64DEFD6 Q38733052-9CD25F80-9346-4E14-BFBD-7D0B15F5BC13 Q38789551-1AA2EFAB-4CD5-4AD1-ACF7-2B9956FCF044 Q38808249-FFA76CED-4186-41C0-B5DD-E3C0335762A4 Q39043413-08AF52FE-A311-4742-AEEF-BBAD3A89C308 Q39585070-1D76A59D-92AE-486E-9044-0D03C1A64AE4 Q42291172-FCC6DE46-F351-4E83-AE7A-E19906634FDC Q45160319-FA432072-C3D7-429A-8A2B-5DB3A04E5126 Q47135720-848C26D7-0EF2-42FB-B685-E46458E60FB4 Q47361686-7FE994E6-17A5-4A37-BDA3-E4B692129E52 Q47843948-C61EE909-09DD-477D-AD23-2B04957E1F3E Q48193633-AB68E349-5ED7-4692-B244-89DBB7B8ED60 Q48339242-1EAF54B0-E890-4D22-AB9A-54E73D9D1A53 Q49805006-D8B13D54-678D-41E9-80E6-212A326FDC43 Q50544077-8F162223-D2D6-4E87-84AF-29CD4666CA0B Q50566797-B8A7DA54-D5CB-4FFA-AF8B-28A6AC263AFD Q50930404-7B901887-2473-4B31-B8A3-5994D1824BB1 Q53359618-EA59D78B-1D5C-49F0-A38D-B71A72CB44A6 Q58785196-E7C78F6F-BDD7-4888-B970-A5FFFBEEE7DB

P2860

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

http://www.wikidata.org/entity/Q43179865

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@en

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@nl

type

label

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@en

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@nl

prefLabel

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@en

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@nl

P1433

Q43179865-B2D8EC9C-302C-424E-8A0B-D8A2C4BC5888

P1476

Q43179865-4006571E-534D-41CE-BE78-B6AD1F690438

P2093

Q43179865-0CBD9614-F4DE-4090-8E7C-DBC48BED36B0

Q43179865-41FDAF28-A3B2-4121-8B07-43D53D598B0D

Q43179865-A18ACE27-EF89-461D-8AE9-3C80730A5A27

P2860

Q43179865-02D9FCBD-DB9E-490C-93FE-671B8811DFF6

Q43179865-05BCE387-0709-4D9C-A7B3-EF2020D27810

Q43179865-0B575B4D-8D47-491D-AD25-88588EA6CB16

Q43179865-0B648E44-77FD-4A6B-878C-6BDDADFB78C4

Q43179865-0C4D0AED-C8CD-4E9E-8BC2-A36A6FFF3F9A

Q43179865-0CFC6BA9-BD47-44EC-97C6-0AEF9E6BDD08

Q43179865-0D08ECA5-19CD-4F8B-8DD8-109F83F6F6CF

Q43179865-0D6D5084-C2EF-4BA8-8A3A-C1F870FB44CB

Q43179865-0E02F9D6-D3EF-413A-BBBE-3185FCED78C5

Q43179865-0F823B19-9714-4907-B7B8-06819EB74F5F

P304

Q43179865-4496CD48-6A39-44A4-B6C2-3EB51F48175C

P31

Q43179865-607FEC30-1923-41B1-8473-EF27EA6DE632

P356

Q43179865-38E56509-4265-4002-AC66-706714F6AE0A

P433

Q43179865-5B48C083-1392-4732-8A97-C423F7AFF009

P478

Q43179865-A153DBBD-16D2-44FD-A06B-29A86AA50BAA

P50

Q43179865-AC8B5894-E934-42DA-9E09-7598FB43C0FC

Q43179865-B6480AD6-C660-4036-AAAA-F0CFBD863A74

P577

Q43179865-A20888DC-D838-4EC8-A9C8-C61EDAB9EA80

P5875

Q43179865-6000FE38-43D3-489F-B8DF-F3D714DE5C0D

P698

Q43179865-83CC7627-F525-494B-B521-61D613A3C5A0

P921

Q43179865-73EEBE25-584E-458C-8F14-B5EDFD89242F

P932

Q43179865-260B5118-1F16-4CDA-97DB-E3B3C08B3850

P356

21624011.2014.968434

P1433

P1476

Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.

@en

P2093

Irena Adkins

http://www.w3.org/2001/XMLSchema#string

Jitka Fucikova

http://www.w3.org/2001/XMLSchema#string

Radek Špíšek

http://www.w3.org/2001/XMLSchema#string

P2860

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

Combining radiotherapy and cancer immunotherapy: a paradigm shift

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Release of chromatin protein HMGB1 by necrotic cells triggers inflammation

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

Calreticulin exposure dictates the immunogenicity of cancer cell death

Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis

Effective elimination of lung metastases induced by tumor cells treated with hydrostatic pressure and N-acetyl-L-cysteine

Bleomycin exerts ambivalent antitumor immune effect by triggering both immunogenic cell death and proliferation of regulatory T cells

By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation

P304

e968434

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/21624011.2014.968434

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Patrizia Agostinis

Abhishek D. Garg

P577

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

271908420

http://www.w3.org/2001/XMLSchema#string

P698

25964865

http://www.w3.org/2001/XMLSchema#string

P921

P932

4352954

http://www.w3.org/2001/XMLSchema#string